The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•29 June 2026•

1 min read

Replimune Group misses Q1 estimates with deeper GAAP loss

Key Facts

1Replimune Group reported GAAP EPS of -$3.38, missing estimates by $0.02.

Amid waning risk appetite for biotech stocks, Replimune Group reported a quarterly loss that exceeded analyst expectations. According to Seeking Alpha, the company posted a GAAP loss per share of -$3.38, missing estimates by $0.02. The result underscores ongoing operational challenges for the pre-revenue biotech firm.

The announcement comes after a mixed earnings season in the biotech sector, where many small-cap firms faced funding headwinds and slower clinical trial progress. Replimune's stock had already fallen 12% over the past quarter, per market data, reflecting investor concern over the lack of near-term catalysts.

Traders are now focused on any pipeline updates, particularly the upcoming Phase 3 trial results for RP1. Broader market catalysts, such as upcoming consumer confidence and inflation data, could also sway sentiment toward high-risk equities in the coming weeks.

Sources: